Recent advances in managing Peyronie's disease.

Peyronie Peyronie’s disease collagenase erectile dysfunction fibrosis non-surgical treatment traction therapy treatment urology

Journal

F1000Research
ISSN: 2046-1402
Titre abrégé: F1000Res
Pays: England
ID NLM: 101594320

Informations de publication

Date de publication:
2020
Historique:
accepted: 15 05 2020
entrez: 11 6 2020
pubmed: 11 6 2020
medline: 20 8 2020
Statut: epublish

Résumé

Treating men with Peyronie's disease remains a challenging problem facing clinicians working across urology and sexual medicine fields. Patients can often be left disappointed by current treatment paradigms, and an overall lack of suitable molecular targets has limited the options for novel, effective medical therapy. Managing men with Peyronie's disease often involves careful counselling alongside multifaceted and possible combination treatments to help improve symptoms whilst ameliorating potential side effects of therapy. We review the latest medical literature and evidence in the contemporary management of Peyronie's disease.

Identifiants

pubmed: 32518629
doi: 10.12688/f1000research.20557.1
pmc: PMC7255896
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright: © 2020 Babu A and Kayes O.

Déclaration de conflit d'intérêts

No competing interests were disclosed.Competing interests: This reviewer is associated with Endo Pharmaceuticals (maker of Xiaflex / CCH) - consultant, advisor, research funding and fellowship support.No competing interests were disclosed.No competing interests were disclosed.

Références

J Urol. 2019 Sep;202(3):599-610
pubmed: 30916626
J Sex Med. 2018 Jul;15(7):1061-1062
pubmed: 29861353
Sex Med. 2016 Jun;4(2):e83-8
pubmed: 26984291
J Urol. 2004 Jun;171(6 Pt 1):2350-3
pubmed: 15126819
Andrology. 2013 Jan;1(1):129-32
pubmed: 23258641
Int Urol Nephrol. 2009;41(3):467-71
pubmed: 19199072
Exp Ther Med. 2017 Nov;14(5):5149-5156
pubmed: 29201230
BJU Int. 2001 Nov;88(7):727-30
pubmed: 11890244
Prog Urol. 2017 Jan;27(1):10-16
pubmed: 27867021
Int J Impot Res. 2016 Sep;28(5):161-6
pubmed: 27250868
J Sex Med. 2018 Oct;15(10):1472-1477
pubmed: 30245025
Urology. 1998 Apr;51(4):620-6
pubmed: 9586617
Nat Rev Urol. 2019 Feb;16(2):79-97
pubmed: 30367131
J Sex Med. 2009 Feb;6(2):558-66
pubmed: 19138361
Res Rep Urol. 2017 Jul 20;9:129-139
pubmed: 28791261
J Sex Med. 2019 Jun;16(6):891-900
pubmed: 30956106
J Sex Med. 2016 Jan;13(1):120-8
pubmed: 26755094
Gut. 2002 Feb;50(2):241-7
pubmed: 11788567
J Urol. 2013 Jul;190(1):199-207
pubmed: 23376148
Curr Urol Rep. 2004 Dec;5(6):478-84
pubmed: 15541219
J Sex Med. 2012 Jan;9(1):288-95
pubmed: 22024053
Eur Urol. 2020 May;77(5):660-661
pubmed: 31810821
Inflamm Allergy Drug Targets. 2013 Dec;12(6):403-9
pubmed: 24304332
Curr Sex Health Rep. 2015 Jun 1;7(2):117-131
pubmed: 26279643
Aging Male. 2019 Mar 16;:1-6
pubmed: 30879382
Asian J Androl. 2011 Mar;13(2):322-5
pubmed: 21102473
J Urol. 1998 May;159(5):1700-7
pubmed: 9554397
Urology. 2017 Jun;104:102-109
pubmed: 28347795
PLoS One. 2016 Feb 23;11(2):e0150157
pubmed: 26907743
J Sex Med. 2017 Nov;14(11):1430-1437
pubmed: 28974406
J Urol. 2006 Jul;176(1):394-8
pubmed: 16753449
J Sex Med. 2016 Jun;13(6):905-23
pubmed: 27215686
Andrology. 2017 Jul;5(4):771-775
pubmed: 28718527
BJU Int. 2010 Jul;106(2):240-8
pubmed: 19863517
BJU Int. 2006 Mar;97(3):570-4
pubmed: 16469028
Urol Ann. 2018 Apr-Jun;10(2):154-158
pubmed: 29719326
J Sex Med. 2013 May;10(5):1259-67
pubmed: 23421851
Int Urol Nephrol. 2015 Oct;47(10):1595-602
pubmed: 26257044
Eur Urol. 2013 Mar;63(3):551-60
pubmed: 23040209
J Urol. 1990 Dec;144(6):1376-9
pubmed: 2231932
Expert Rev Med Devices. 2018 Aug;15(8):517-526
pubmed: 30016597
J Sex Med. 2005 Sep;2(5):709-15
pubmed: 16422829
J Urol. 2006 Jun;175(6):2115-8; discussion 2118
pubmed: 16697815
J Sex Med. 2014 Jun;11(6):1593-8
pubmed: 24708140
J Sex Med. 2015 Jan;12(1):248-58
pubmed: 25388099
Int J Impot Res. 2019 Jul;31(4):256-262
pubmed: 30194372
J Sex Med. 2015 Jul;12(7):1533-44
pubmed: 26062100
Urologia. 2013 Apr 24;80 Suppl 22:28-30
pubmed: 23334885
BJU Int. 2017 Nov;120(5):717-723
pubmed: 28612401
J Urol. 2015 Sep;194(3):754-8
pubmed: 25804087
Glob J Health Sci. 2014 Sep 18;6(7 Spec No):23-30
pubmed: 25363175
Eur Urol. 2012 Sep;62(3):543-52
pubmed: 22658761
J Urol. 2007 Mar;177(3):972-5
pubmed: 17296390
Andrology. 2013 Jan;1(1):120-8
pubmed: 23258640
World J Mens Health. 2016 Apr;34(1):40-6
pubmed: 27169128
Urol Res. 1982;10(3):135-40
pubmed: 6291216
Drugs. 2016 Oct;76(16):1523-1528
pubmed: 27770352
Biochim Biophys Acta. 2013 Jul;1832(7):1049-60
pubmed: 23046809
J Sex Med. 2014 Feb;11(2):506-15
pubmed: 24261900
J Urol. 2015 Sep;194(3):745-53
pubmed: 26066402
Eur Urol. 2005 Apr;47(4):530-5; discussion 535-6
pubmed: 15774254
Eur Urol. 2019 Feb;75(2):329-340
pubmed: 30344087
Andrology. 2018 Jan;6(1):117-126
pubmed: 29266877
Andrology. 2018 Jul;6(4):564-567
pubmed: 29733116
Sex Med. 2019 Dec;7(4):459-463
pubmed: 31445974
J Sex Med. 2015 Feb;12(2):313-27
pubmed: 25496134
Eur Urol. 2018 Dec;74(6):767-781
pubmed: 30237020
Andrology. 2014 Mar;2(2):244-51
pubmed: 24574095
BJU Int. 2019 Apr;123(4):694-702
pubmed: 30365247

Auteurs

Asrit Babu (A)

Department of Urology, Leeds Teaching Hospitals, Leeds, UK.

Oliver Kayes (O)

Department of Urology, Leeds Teaching Hospitals, Leeds, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH